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ABSTRACT
The alterations in carbohydrate metabolism that fuel tumor growth have been 
extensively studied. However, other metabolic pathways involved in malignant progression, 
demand further understanding. Here we describe a metabolic acyl-CoA synthetase/ stearoyl-
CoA desaturase ACSL/SCD network causing an epithelial-mesenchymal transition (EMT) 
program that promotes migration and invasion of colon cancer cells. The mesenchymal 
phenotype produced upon overexpression of these enzymes is reverted through reactivation 
of AMPK signaling. Furthermore, this network expression correlates with poorer clinical 
outcome of stage-II colon cancer patients. Finally, combined treatment with chemical 
inhibitors of ACSL/SCD selectively decreases cancer cell viability without reducing normal 
cells viability. Thus, ACSL/SCD network stimulates colon cancer progression through 
conferring increased energetic capacity and invasive and migratory properties to cancer 
cells, and might represent a new therapeutic opportunity for colon cancer treatment.
INTRODUCTION
Colorectal cancer (CRC) is one of the most deathly 
tumors worldwide. In addition to genetic modifications, 
factors causing metabolic alterations such as obesity, 
sedentarism and westernized diet, are risk factors for the 
disease [1]. Metabolic reprogramming is a distinguished 
cancer hallmark [2]. It is well known the Warburg effect by 
which cancer cells preferentially drive glucose metabolism 
to lactate production under aerobic conditions [3]. In 
addition to carbohydrate metabolism, other metabolic 
pathways have been found to be altered in cancer [4]. 
Lipid metabolism, represents an extremely relevant source 
of energy and structural and biosynthetic resources [5, 6].
De novo fatty acid synthesis is required for 
membrane production, essential for cell growth and 
proliferation. In addition, an appropriate ratio between 
saturated and monounsaturated fatty acids (SFA and 
MUFA, respectively) is needed for proper membrane 
fluidity and cell function. An increased content of MUFA 
has been observed in several cancers [7] and it has been 
proposed as a predictive marker [8]. The rate-limiting 
enzyme converting SFA into MUFA is steraroyl-CoA 
desaturase-1 (SCD), which introduces a double bound into 
palmitic acid and stearic acid giving rise to palmitoleic 
and oleic acid, respectively [9]. SCD have been 
described upregulated in several types of human tumors 
and its expression has been correlated with malignant 
transformation, proliferation and survival [10–14].
Acyl-CoA synthetases (ACSL) catalyze the 
conversion of long chain fatty acids to acyl-CoA, which 
is critical for phospholipid and triglyceride synthesis, 
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lipid modification of proteins as well as for fatty acid 
β-oxidation [15]. These enzymes have been related to 
carcinogenesis [16, 17]. Although involved in the same 
reaction, enzymes of ACSL family differ in substrate 
specificity, subcellular localization, and tissue distribution. 
In fact, these enzymes use saturated and unsaturated fatty 
acids of 8–22 carbons as substrates with the exception 
of ACSL4 that shows a clear preference for arachidonic 
acid as a substrate [6]. ACSL4 increases proliferation, 
tumor growth and survival in breast, prostate, colon 
and liver malignancies [18–21]. Remarkably, ACSL4 
overexpression channels fatty acids preferentially 
towards phosphatidylinositol, an effect not observed 
for ACSL1 [22]. ACSL1 has been recently involved in 
lipid metabolism alterations in cancer [23], including in 
a screening in colon cancer of lipid metabolism-related 
genes recently conducted in our research group [24, 25].
Epithelial-mesenchymal transition (EMT) is a conserved 
morphogenetic program characterized by the loss of epithelial 
phenotype and the gain of mesenchymal features [26]. 
Epithelial cells discard their cell polarity and cell-cell adhesion 
and acquire a mesenchymal morphology with migration and 
invasion capability. These properties promote metastasis and 
the development of several neoplasias [27]. Loss of E-Cadherin 
and nuclear translocation of β-Catenin constitute known EMT 
biomarkers. β-Catenin trans location to the nucleus leads to 
invasion genes transcription [28]. This requires avoiding 
β-Catenin rapid cytosolic degradation by the proteasome, 
achieved upon GSK3β phosphorylation [29]. An implication of 
carbohydrates metabolism in the EMT phenotype acquisition 
and maintenance has been reported [30, 31] although no 
connection has been yet described with fatty acid metabolism.
Here we identify a cooperative metabolic network 
comprising ACSL1, ACSL4 and SCD, involved in CRC 
progression. The simultaneous overexpression of ACSL1, 
ACSL4 and SCD induces EMT, increases cellular migration 
and invasion and stimulates several survival pathways. 
Besides, the combination of low doses of pharmacological 
inhibitors for ACSL and SCD, dramatically decreases 
cancer cell viability in a synergistic manner. Moreover, such 
combination also reduces cell viability of chemotherapy 
resistant colon cancer cells without having any effect in normal 
colonocytes. Finally, the clinical relevance of these findings is 
underscored in CRC patients with tumors displaying ACSL1/
ACSL4/SCD simultaneous overexpression that show an 
increased risk of relapse compared to other patients within 
the same clinicopathological stage.
RESULTS
Lipid metabolism enzymes overexpression 
confers EMT properties to colon cancer cells
The aim of this study was to perform a comparative 
analysis of the potential involvement of ACSL1 and ACSL4 
in CRC, in addition to analyzing whether their combination 
with the related enzyme SCD might increase tumorigenesis 
due to the probable role of SCD in preventing lipotoxic 
effects that could result from ACSL overexpression. For 
this purpose we generated human colon cancer stable 
cell lines overexpressing either ACSL1, ACSL4 or SCD 
(ACSL1 cells, ACSL4 cells, and SCD cells, respectively) 
or the three genes simultaneously (x3 cells), transducing 
the DLD-1 CRC cell line with specific lentiviruses. An 
equivalent control vector which does not express any ORF 
was also used to generate the No ORF cell line. Transcript 
levels of ACSL1, ACSL4 and SCD were measured to 
ensure that stable expression of the constructs was achieved 
(Figure 1A), which was further confirmed by Western Blot 
analysis of the proteins levels (Figure 1B).
Unlike No ORF controls, nor any of the cell lines 
overexpressing any of these genes individually, x3 cells 
displayed a more spindle-like shape with a more scattered 
distribution, resembling mesenchymal or fibroblast-like 
phenotype (Figure 1C). Since this morphological change 
resembled an EMT phenotype characterized by loss of 
cell-cell adhesion, we next analyzed the expression of the 
epithelial marker E-Cadherin. As shown in Figure 1D, 
the membrane-associated pattern of expression of 
E-Cadherin was disrupted upon ACSL1, ACSL4 and 
SCD simultaneous overexpression. Mislocalization of 
E-cadherin was more evident in the areas where the more 
fusiform and rounded x3 cells were present (Figure 1D, 
bottom panel, arrow). Moreover, loss of β-Catenin from 
the membrane and a clear increase in nuclear localization 
was also found in x3 cells when compared with No ORF 
control cells (Figure 1E). This is also in agreement with 
a loss of epithelial characteristics and gain of an EMT 
phenotype, since its translocation to the nucleus would 
lead to the transcription of invasion genes [28]. Figure 1F 
shows how GSK3β inhibitory phosphorylation is 
highly increased in x3 cells, allowing β-Catenin nuclear 
translocation. β-Catenin acts as a transcriptional 
coactivator at the nucleus promoting the transcription of 
EMT genes [32]. Accordingly, together with a decrease in 
the expression of the epithelial markers E-Cadherin, K18 
and Na+/K+ATPase β1, x3 cells increased the expression 
levels of EMT associated genes N-cadherin, Slug and 
Vimentin (Figure 1G) which are normally not expressed in 
the markedly epithelial DLD-1 cells.
Accordingly with the lack of any morphological 
change, no mislocalization of E-cadherin nor changes 
in epithelial markers were observed in cell lines singly 
overexpressing any of these genes (Supplementary 
Figure S1A–S1B). Interestingly, an increase in GSK3β 
phosphorylation was also observed in SCD cells 
(Supplementary Figure S1C). In contrast, only cells 
overexpressing ACSL1, but not ACSL4 or SCD (data not 
shown) displayed an up-regulation of N-cadherin and Slug 
expression (Supplementary Figure S1D). These results 
suggest that each gene might be contributing in different 
aspects of EMT, though the cooperation of the three genes 
is needed to trigger the EMT program.
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Cells undergoing EMT have been described to 
present cancer stem cells features [33]. Accordingly, x3 
cells were significantly enriched in the well-established 
markers of CRC stem cells CD44, LGR5, ALDH1A1, 
EpCAM and CD29 when compared with No ORF cells 
(Figure 1H). Moreover, x3 cells form tridimensional 
colonies with differential morphologies when grown 
in matrigel. While No ORF cells displayed the normal 
DLD-1 spheroid round morphology termed as “mass” 
[34, 35] (Figure 1I, left panel), x3 cells whether presented 
“grape-like” spheroids with loose cell-cell contacts 
(Figure 1I, central panel) or even “stellate” colonies 
with invasive projections able to bridge several cell 
colonies (Figure 1I, right panel). This again highlights 
the more mesenchymal behavior of x3 cells and suggests 
an invasive capacity for these cells.
Figure 1: ACSL1, ACSL4 and SCD overexpression induces EMT in CRC cells. A. Stable cell lines overexpressing ACSL1, 
ACSL4 and SCD, alone or in combination (x3) were generated using lentiviral transduction and expression levels of every gene were 
measured by RT-QPCR. B. Protein expression levels of ACSL1(upper band), ACSL4 and SCD for each cell line were detected by Western 
Blot with specific antibodies. β-Actin detection was used as a loading control. C. Representative phase contrast images showing atypical 
morphology of x3 cells compared to control No ORF cells. Scale bars, 100 μm. D–E. Representative immunofluorescence images of 
E-Cadherin (green) (D) or β-Catenin (green) (E) cellular distribution of No ORF and x3 cells. Arrows indicate the different expression 
patterns in the cellular distribution of E-Cadherin (D) or β-Catenin (E) in both types of cells. Nuclei were stained with DAPI (blue) and 
equivalent phase contrast images were taken. Scale bars, 50 μm. F. Levels of GSK3 phosphorylation detected by Western Blot using a 
phospho-specific antibody (Ser21/9). Total GSK3β levels detection and Ponceau-stained band served as loading controls. Bottom panel: 
Quantification of bands intensity showing the ratio of phosphorylated to total protein. (Continued )
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ACSL/SCD metabolic network fuels migration, 
invasion and cell survival
The acquisition of migratory and invasive properties 
is a general feature of cells undergoing EMT, crucial for 
metastasis formation and cancer progression. In order to 
check if the combination of ACSL and SCD overexpression 
could confer cancer cells a gain of migratory capacity, we 
performed wound healing assays. Figure 2A shows how x3 
cells present an increased migration ability compared to 
No ORF cells. As illustrated in the magnification, x3 cells 
close the wound upon random migration, characteristic 
of a mesenchymal behavior. In contrast, No ORF control 
cells, ACSL1, SCD, and more markedly ACSL4, display 
the collective unidirectional migration of cohesive epithelial 
sheets. Furthermore, poorly invasive DLD-1 cells gain 
the ability to invade through Matrigel (Figure 2B) upon 
ACSL1, ACSL4 and SCD simultaneous overexpression 
(x3). The invasion capacity was also increased upon 
individual overexpression, especially in the case of ACSL1 
cells. However, any of these individual effects was less 
prominent that the one observed in x3 cells. These results 
highlight the cooperative effect in promoting migration and 
invasion achieved when these three metabolic genes act in 
a combined manner.
Cancer cells often use metabolic strategies to 
promote cell survival and proliferation. To analyze 
whether an increased lipid metabolism caused by ACSL1, 
ACSL4 and SCD overexpression could be implicated in 
these processes, we first performed clonogenic assays to 
monitor long-term growth and survival. Figure 2C shows 
that x3 cells present more than twice efficiency in colony 
formation compared to control cells. In contrast, none of 
the individual overexpression caused this increase in the 
number of colonies formed indicating again that it is the 
combination of the three genes that confers the cells the 
more aggressive characteristics.
To directly assay cell proliferation we analyzed the 
incorporation of EdU as a measure of DNA synthesis rate. 
No significant changes in proliferation were found in any 
of the stable cell lines (Figure 2D). Since colony formation 
needs cell proliferation, we also performed those EdU 
assays in conditions of confluence to make these assays 
more comparable to the growth conditions in the colonies 
produced during clonogenic assays. Again, we do not find 
substantial differences in proliferation in any of the cell lines 
(Supplementary Figure S2). A number of EMT regulators 
have been reported not to increase proliferation, and invasive 
cells associated to decreased cell cycle progression [36, 37]. 
We next analyzed Erk and Akt activation, two well-known 
Figure 1: (Continued ) ACSL1, ACSL4 and SCD overexpression induces EMT in CRC cells. G. RT-QPCR analysis of 
epithelial (E-Cadherin, K18 and Na+/K+ATPase β1) and mesenchymal genes (N-Cadherin, Slug and Vimentin) for x3 cells compared to 
levels in No ORF control cells. H. The expression levels of the colon cancer stem cell markers CD44, Lgr5, ALDH1A1, EpCAM and CD29 
were measured by RT-QPCR in x3 cells and compared to the levels in No ORF control cells. I. Phase contrast pictures showing the different 
morphology of spheroids formed by No ORF and x3 cells cultured under 3D on-top assay conditions. Scale bars, 100 μm. Experiments in 
A, G and H were performed in triplicates (n = 3). Results represent the mean ±SD (n = 3). *, p < 0.05, **, p < 0.01, ***, p < 0.001.
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pathways for cell survival involved in EMT induction mainly 
through GSK3β regulation [38]. We found a significant 
activation of both cascades in x3 cells (Figure 2E). Besides, 
a clear increase in Erk and Akt phosphorylation was found 
in SCD cells, as well as in ACSL4 cells in the case of Akt 
phosphorylation. These partial activations per se may 
be insufficient but may contribute to the full effect and 
phenotype observed in x3 cells.
All these data suggest that unlike other tumor 
metabolic pathways such as the Warburg effect, the 
ACSL/SCD network acts specifically promoting invasive 
and pro-survival properties without major effects on cell 
proliferation. In agreement with that, x3 cells did not show 
increased glycolytic activity when compared with No ORF 
control cells (Figure 2F). This reveals that EMT promotion 
might require particular metabolic advantages other than 
pro-proliferative aerobic glycolysis.
AMPK signaling counteracts the EMT 
phenotype triggered by the ACSL/SCD 
signaling network
In addition to classical oncogenic pathways [38], 
nutrient sensing and inflammation regulators have 
been more recently added to the list of EMT-inducers 
[39, 40]. Since ACSL/SCD overexpression may represent 
Figure 2: Combination of ACSL with SCD overexpression stimulates migration, invasion and colony formation 
without major effects on proliferation. A. Phase contrast pictures of wound healing assay comparing migratory capacities of No 
ORF, ACSL1, ACSL4, SCD and x3 cells. Magnification (right panels) shows the different behavior of control and x3 cells at 36 hours of 
wound closure. Scale bars, 100 μm. B. Boyden chamber transwell assay of invasion through Matrigel. After 48 hours, cells were fixed and 
stained with crystal violet (bottom panels) and counted under an optical microscope. Migratory cells were quantified as the average number 
of cells found in five random microscope fields in three independent inserts. Scale bars, 50 μm. (Continued)
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an energetic advantage, we wondered if the master 
regulator of energy balance, AMPK, was involved. 
This kinase, considered to act as a tumor suppressor by 
inhibiting tumor metabolism and associated cell growth 
signaling pathways [41] has been described to suppress 
EMT by regulating the Akt-MDM2-Foxo3 signaling axis 
[42]. Accordingly, treatment with three different AMPK 
activators; metformin, phenformin and AICAR, was able 
to rescue the DLD-1 epithelial phenotype (Figure 3A).
Besides sharing arachidonic acid as a substrate, 
ACSL4 regulates COX-2 expression and thus 
prostaglandin production [19], also implicated in cell 
malignancy and EMT promotion [43]. Since x3 cells, but 
not any of individually overexpressing cell lines, show 
increased levels of COX-2 expression (Figure 3B); we 
surmised that x3 EMT might be mediated by a COX-2 
dependent mechanism. Conversely, treatment with the 
COX-2 inhibitor NS-398 had no effect on the x3 cells 
phenotype reversion (Figure 3C, central panel). Moreover, 
despite the strong Akt activation in x3 cells (Figure 2E), 
the treatment with Akt inhibitor IV (Figure 3C, right 
panel) was also inefficient to revert x3 mesenchymal 
features. This drug only inhibited cell viability of both 
cell lines without altering their morphological features. 
These data pointed towards AMPK signaling as key for 
maintaining the DLD-1 cells epithelial phenotype. This 
was further demonstrated by analysis of the downstream 
AMPK target, Acetyl-CoA Carboxylase (ACC), which 
is inactivated upon phosphorylation at Ser79 (P-ACC). 
The ACC inhibitory phosphorylation was induced upon 
metformin or phenformin treatment in x3 cells (Figure 
3D). Furthermore, metformin treatment stimulated the 
expression of the epithelial markers E-Cadherin, K18 and 
Na+/K+ATPase β1 and decreased the expression levels of 
the EMT-induced genes N-Cadherin and Slug in x3 cells 
without increasing those levels in control No ORF cells 
(Figure 3E).
Stage-II CRC patients with simultaneous 
overexpression of ACSL1, ACSL4 and SCD 
have worse clinical outcome
In order to determine the clinical relevance of ACSL/
SCD network activation in CRC, we analyzed the putative 
association between the simultaneous overexpression of 
ACSL1, ACLS4 and SCD with clinical outcome in a 
set of 77 samples from stage-II CRC patients. Towards 
this aim we have recently developed a global analysis of 
lipid metabolism-related genes [25]. Median follow-up 
of these patients was 71.5 months. The 3-year disease 
Figure 2: (Continued) Combination of ACSL with SCD overexpression stimulates migration, invasion and colony 
formation without major effects on proliferation. C. Clonogenic assay quantification. Individual cells were plated and colonies 
formed were grown during 2 weeks. Data are presented as the average number of colonies resultant for each cell line. D. Quantification 
using fluorescence microscopy of EdU incorporation as a measure of cell proliferation. E. Erk1/2 and Akt phosphorylation were detected 
by Western Blot with phospho-specific antibodies (Tyr204 Erk and Thr308 Akt). Total Erk and Akt were used as their respective controls. 
Bottom panels: Quantification of bands intensity showing the ratio of phosphorylated to total protein. F. Quantification of extracellular 
L- Lactate produced by No ORF and x3 cells. Experiments in B, C, D and F were performed in triplicates (n = 3). Results represent the 
mean ±SD (n = 3). *, p < 0.05, **, p < 0.01.
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free survival (DFS) was 72.3%, 22 patients (28.57%) 
relapsed. Clinico-histopathological characteristics of 
these patients are detailed in Supplementary Table S1. An 
initial screening performed showed that 16 out of 70 lipid 
metabolism-related genes analyzed, including ACSL1, 
ACLS4 and SCD, might have a putative association 
with tumor aggressiveness [25]. Thus, we performed 
a comparative analysis of the relationship between the 
individual expression of these genes and their combined 
overexpression in these patients. As expected from the 
screening, Kaplan-Meier plots for disease free-survival of 
ACLS1, ACSL4 or SCD showed an association between 
high expression of each of these genes and poorer 
clinical outcome (Figure 4A, 4B and 4C). Moreover, 
the multivariable model x3 (combined expression of 
ACSL1, ACSL4 and SCD) showed that the simultaneous 
overexpression of the ACSL/SCD network resulted in a 
stronger and more potent association with patient relapse 
(Figure 4D and Table 1), confirming the acquisition of 
increased aggressive properties of CRC tumors with these 
characteristics.
We validated these results in an independent 
and bigger cohort of 119 stage II CRC patients with a 
median follow-up of 43 months and 3-year DFS of 86.1% 
respectively, from which 18 patients relapsed (15.3%) 
(Clinico-pathological characteristics summarized in 
Supplementary Table S1). The univariate cox regression 
analysis in this validation group also showed a statistical 
association between overexpression of each gene and 
clinical outcome (Figure 4, Table 1). The multivariate 
analysis in this validation group further demonstrated 
that the combined overexpression of these genes was 
associated with a higher increased risk of relapse of 
stage-II CRC patients, with higher power and statistical 
strengthening than any of these genes individually (x3: 
HR (95% CI) = 8.68 (1.9–39.66); p = 6e-04), which is 
more than 2-fold higher than any of these genes separately, 
results that were confirmed after adjusting for clinical 
confusing factors (Table 1).
These results, not only show the clinical relevance 
of the overexpression of these genes in CRC, but also 
demonstrate that their combination is associated with an 
Figure 3: AMPK activation rescues normal DLD-1 epithelial phenotype. A. Representative phase contrast pictures of No ORF 
and x3 cells treated either with 5 mM metformin, 1 mM phenformin, 1 mM AICAR or vehicle (water) for 48 hours. Scale bars, 100 μm. 
B. COX-2 expression levels of x3 cells compared to control No ORF cells, measured by RT-QPCR. C. Pictures represent cells treated for 
48 hours either with the COX-2 inhibitor NS-398 (10 μM), the Akt inhibitor IV (Akt-inIV, 2 μM), or with an equivalent amount of DMSO 
as control. Scale bars, 100 μm. (Continued)
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increased aggressiveness of CRC tumors in a clinical setting. 
Collectively, these results imply that ACSL1, ACSL4 and 
SCD increased expression might act as a marker of poor 
prognosis which contributes to reduced disease free survival 
of colon cancer patients. Very likely, the EMT program 
triggered by the ACSL1/ACSL4/SCD axis would be 
implicated in facilitating the spread of the disease.
Combined pharmacological inhibition of the 
ACSL/SCD network synergy to selectively inhibit 
cancer cells viability and mesenchymal features
The robust protumor action of ACSL1/ACSL4/
SCD network, together with the fact that all three of them 
are lipid metabolism enzymes, makes these druggable 
proteins attractive targets for cancer therapy. For this 
reason, we evaluated the combined effect on colon cancer 
cell viability of Triacsin C, a specific inhibitor of ACSL, 
and the SCD inhibitor A939572, both previously reported 
to reduce tumor growth both in vitro and in vivo [14, 17]. 
Triacsin C was able to decrease cell viability in DLD-1 
and SW620 cell lines in a dose-dependent manner (Figure 
5A). A similar effect was achieved upon treatment with 
A939572 (Figure 5B). Since the use of high concentrations 
of pharmacological inhibitors may cause side effects and act 
on other pathways, the combination of the two compounds 
might inhibit ACSL/SCD network and exert a similar action 
using much lower concentrations of both compounds .
Lower concentrations of Triacsin C and A939572 
alone or in combination were used in a panel of colon 
cancer cell lines (Figure 5C). As expected, treatment with 
1 μM Triacsin C or with 0.5 μM A939572 moderately 
decreased DLD-1 and SW620 cells viability, but 
importantly, the combined action of both inhibitors caused 
a strong cancer cell viability reduction. Furthermore, 
Triacsin C and A939572 individually had no effect on the 
viability of the more resistant HT-29 and LS174T cells; 
however, a potent inhibition was observed when those low 
doses of both compounds were used (Figure 5C).
In addition, to analyze the effect of these compounds 
on CRC cells resistant to conventional chemotherapy, we 
used a subclone of SW620 cells previously described [44], 
Figure 3: (Continued) AMPK activation rescues normal DLD-1 epithelial phenotype. D. Western blotting of ACC phosphorylation 
upon 48 hours of metformin (5 and 10 mM) or phenformin (0.5 and 2 mM) treatment in No ORF and x3 cells. Total protein extracts were blotted 
using a phospho-specific antibody (Ser79) and a total ACC antibody. β-Actin detection was used as a loading control. E. RT-QPCR analysis 
shows mRNA levels of epithelial markers (E-Cadherin, K18 and Na+/K+ATPase β1) upon 48 hours of metformin treatment (5 and 10 mM) 
in No ORF and x3 cells (left panel). Similarly, right panel presents the levels of the mesenchymal markers N-Cadherin and Slug in these cell 
lines under similar treatments. The values for every gene are presented as fold change referenced to their respective control (0 mM metformin) 
within each cell line. Results in C and E were performed in triplicates, and represent the mean ±SD. *, p < 0.05, **, p < 0.01, ***, p < 0.001.
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Figure 4: Prognostic value of ACSL1/ACSL4/SCD individual or simultaneous (x3) overexpression in early-stage CRC 
patients. Kaplan-Meier plots representing DFS for ACSL1 A. ACSL4 B. SCD C. and x3 D. overexpressing early-stage CRC patients and 
p Log Rank value in the training and validation groups are shown.
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which is resistant to 5-Fluorouracil. The drugs had little 
(Triacsin C), or no effect (A939572) on SW620–5FU-R 
when applied separately. Nonetheless, a strong cooperative 
effect was found upon simultaneous treatment with ACSL 
and SCD inhibitors (Figure 5D).
Since the EMT program observed in x3 cells is 
triggered by the combined action of ACSL with SCD, 
we wanted to assay the effect on EMT of their inhibitors. 
Combined treatment with low doses of these drugs was 
able to reverse the mesenchymal phenotype of x3 cells 
to a situation resembling No ORF cells (Figure 5E). 
Furthermore, this was accompanied by an increase 
in the expression of epithelial markers and a reduced 
expression of EMT-genes in x3 cells (Figure 5F). Hence, 
the pharmacological inhibition of ACSL/SCD network is 
able to counteract the x3 cells EMT features.
Finally, the ability of a compound to discriminate 
cancer cells from their normal counterparts is the basis for 
successful cancer treatment. For this reason, we assayed 
the effect of Triacsin C and A939572 on the viability of 
normal colonocytes. Very importantly, the same inhibitors 
concentrations that caused a massive loss of viability of 
colon cancer cell lines (Figure 5C and 5D) were completely 
ineffective when applied to normal colonocytes CCD18Co 
(Figure 5G). This was further confirmed using another 
normal colon cell line, CCD841 (Figure 5H) resulting in 
a similar behavior. Thus, the inhibition of ACSL1/ACSL4/
SCD axis by means of the selective effect of these drugs on 
cancer cells arises as a promising therapeutic strategy.
DISCUSSION
We show for the first time how the overexpression 
of lipid metabolism genes can lead to EMT induction and 
increased migratory and invasive properties. ACSL1/
ACSL4/SCD overexpression in CRC cells causes a 
phenotypic switch to a mesenchymal-like condition 
characterized by rounded cell morphology and E-Cadherin 
and β-Catenin mislocalization (Figure 1D and 1E). 
This phenotypic change, which leads to an increased 
migration and invasion (Figure 2) is only achieved upon 
overexpression of the three proteins, presumably having 
each of them more partial but differential functions. ACSL1 
may be an initiator of the process since its overexpression 
stimulates EMT genes expression (Supplementary 
Figure S1D). ACSL1 seems also to be fundamental for 
invasive abilities (Figure 2B) which could be caused by 
an increased expression of invasive genes such as matrix 
degrading enzymes. For its part, SCD overexpression 
strongly increases inhibitory phosphorylation of GSK3β 
(Supplementary Figure S1C). This may be a consequence 
of SCD overexpression-induced Akt activation (Figure 2E) 
which phosphorylates and inactivates GSK3β [38, 45, 46], 
avoiding β-catenin degradation and allowing further EMT 
signaling . Indeed, SCD knock-down impairs β-catenin 
signaling and inhibits EMT-like behavior of metastatic 
breast cancer cells [47]. SCD may maintain the network 
signaling through Erk and Akt stimulation (Figure 2E) 
Table 1: Univariate and Multivariate Cox regression analyses for Disease-free survival of the 
ACSL1, ACSL4 and SCD genes, the multivariable model x3 (combined expression of ACSL1, 
ACSL4 and SCD) in stage II CRC samples from the training group and the validation group
Variable Training group (n = 77) Validation group (n = 119)
Low Risk High Risk Unadjusted Adjusted# Low Risk High Risk Unadjusted Adjusted#
R N R N HR (95% 
CI)
P HR (95% 
CI)
P R N R N HR (95% 
CI)
P HR (95% 
CI)
P
ACSL1 10 51 12 26
2.93 
(1.26–
6.81)
0.013
2.34 
(0.91–
6.02)
0.082 5 61 13 58 3.12 
(1.11–8.76)
0.021
3.86 
(1.16–
12.79)
0.017
ACSL4 9 54 13 23
4.92 
(2.09–
11.62)
0
5.6 (2.19–
14.32)
0 8 78 10 41 2.59 (1.02–
6.57)
0.045
2.31 
(0.85–
6.27)
0.1
SCD 3 26 19 51
3.57 
(1.06–
12.08)
0.018
3.13 (0.9–
10.93)
0.046 3 57 15 62 5.32 (1.54–
18.38)
0.002
4.08 
(1.12–
14.9)
0.017
x3 6 46 16 31
5.36 
(2.09–
13.74)
0.000
4.99 
(1.81–
13.77)
0.001 2 58 16 61
9 (2.07–
39.21)
0.0002
8.68 (1.9–
39.66)
6E-04
Abbreviations: HR (95% CI), hazard ratio and corresponding 95% confidence interval from adjusted or unadjusted Cox 
regression analyses; P, p value from adjusted or unadjusted Cox regression analyses; N, N° of patients in each risk group; R, 
N° of patients with relapse.
#Cox regression analyses were adjusted for T stage, Vascular invassion, Perineural invassion, Bowel Obstruction/
Perforation and Age > 70.
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which are key for EMT programs [48]. In fact, oleic acid, 
the main product of SCD, activates Akt pathway while 
palmitic acid has the opposite effect [49]. Very likely, SCD 
maintenance of the cancer preferred MUFA/SFA ratio, is 
the driving force of Erk and Akt signaling as observed in 
lung and prostate cancers [10, 50]. Hence, the SCD-induced 
increase in MUFA content seems crucial to maintain 
EMT and tumor dissemination. We found no evidence 
highlighting any specific role of ACSL4 overexpression 
in EMT onset. However, due to its substrate preference for 
arachidonic acid, and the reported crosstalk with COX-2 
[18, 19], ACSL4 could favor prostaglandin production and 
other inflammatory mediators of EMT [40, 43]. Conversely, 
ACSL4-overexpressing cells display a more epithelial-like 
behavior in wound healing assays (Figure 2A). It could be 
possible that upon feeding EMT, ACSL4 could provide the 
necessary plasticity to revert to the epithelial phenotype 
through a mesenchymal–epithelial transition (MET) [26], 
crucial for the growth and establishment of metastasis.
Even though Warburg-like metabolism seems 
to be present in most malignancies, alternative energy 
sources can be used depending on the tumor context 
Figure 5: Synergistic effect of ACSL and SCD inhibitors on CRC cells. A–B. Dose–response curves of the MTT cell viability 
assays after 48 hours treatment of SW620 and DLD-1 colon cancer cells with increasing concentrations of ACSL inhibitor Triacsin C (A) or 
SCD inhibitor A939572 (B). C. MTT cell viability assays in DLD-1, SW620, HT-29 and LS174T colon cancer cell lines show synergistic action 
on cell viability of low doses of Triacsin C (1 μM) and A939572 (0.5 μM) upon 48 hours treatment. D. Response of SW620–5FU-R cells in 
MTT assays to the 48 hours treatment with different concentrations of Triacsin C and/or A939572. E. Representative phase contrast pictures of 
No ORF and x3 cells treated with vehicle (DMSO), Triacsin C (1 μM) and/or A939572 (0.1 μM) for 48 hours. Scale bars, 100 μm. (Continued )
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[4], suggesting an intrinsic metabolic flexibility for 
cancer cells. ACSL/SCD network promotes migration 
and invasion without main effects on cell proliferation 
(Figure 2). Hence, it is reasonable to think that an 
enhanced lipid metabolism has more implications other 
than support proliferation like pro-proliferative aerobic 
glycolysis. In fact, x3 cells show no increase, but a 
slight decrease in lactate production (Figure 2F). Altered 
lipid metabolism may be more directed to provide 
EMT and invasion. Interestingly, it has been reported a 
monoacylglycerol lipase-governed fatty acid network 
which drives invasion and cancer pathogenesis [51]. This 
could be initially driven by an EMT mechanism as the one 
generated by the ACSL1/ACSL4/SCD axis. On the other 
hand, lipids are important signaling molecules triggering 
a number of protumor pathways. SCD inhibition decreases 
the synthesis of PIP3, crucial for Pi3K/Akt signaling 
[10]. Furthermore, arachidonic acid, the main ACSL4 
substrate, is one of the most common fatty acids of PIP3. 
ACSL, especially ACSL4, also stimulate fatty acid entry 
into β-oxidation [15] which generates not only ATP but 
also redox power necessary to counteract tumor oxidative 
stress [5]. Lipid anabolism and catabolism alterations have 
been proposed to coexist in tumor cells [52]. Therefore, 
an increased fatty acid catabolism caused by ACSL 
overexpression, along with increased de novo fatty acid 
synthesis and advantageous MUFA content upon SCD 
upregulation could generate an array of protumorigenic 
signals capable of supporting malignancies through an 
initial EMT program.
The abnormal metabolism of x3 cells provides 
an energetic advantage crucial to EMT promotion and 
invasiveness. Such is the case, that if energy homeostasis 
is disrupted either upon AMPK signaling reactivation 
(Figure 3) or upon simultaneous chemical inhibition of 
ACSL and SCD (Figure 5E and 5F), epithelial features 
are rescued. Defective AMPK signaling seems to be 
the main mechanism to drive EMT by the ACSL/SCD 
network since interference with other pathways already 
described to cause EMT such as Pi3K/Akt or COX-2 
[43, 48] had no effect on the original phenotype recovery 
(Figure 3C). AMPK could be suppressing EMT through 
the regulation of the Akt-MDM2-Foxo3 signaling axis 
as recently proposed [42]. This is in agreement with the 
increased Akt signaling observed in x3 cells (Figure 2E). 
However, Akt inhibitor IV fails to revert EMT suggesting 
additional pathways affected by AMPK signaling that are 
also needed for a complete rescue. On the other hand, 
SCD downregulation activates AMPK [10, 53] but no link 
has been established between AMPK and ACSL. Since 
free fatty acids are able to activate AMPK [54] ACSL 
overexpression could prevent this activation through the 
conversion of fatty acids into Acyl-CoAs.
ACSL1 implication in triglyceride synthesis [55] 
together with the function of ACSL4 in phospholipids 
channeling [22] suggests an increased lipid synthesis upon 
Figure 5: (Continued ) Synergistic effect of ACSL and SCD inhibitors on CRC cells. F. RT-QPCR analysis showing the x3 cells 
mRNA levels of the epithelial markers E-Cadherin, K18 and Na+/K+ATPase β1 and the mesenchymal markers N-Cadherin and Slug upon 
48 hours of treatment with Triacsin C (1 μM) and/or A939572 (0.1 μM). G–H. MTT cell viability assays in normal colonocytes. CCD18Co 
(G), or CCD841 cells (H), were treated for 48 hours with different concentrations of Triacsin C and/or A939572. Data are represented as 
the mean ±SD (n = 3) in all the plots. C = Vehicle, T = Triacsin C, A = A939572, A+T = A939572+Triacsin C. *, p < 0.05, ***, p < 0.001.
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ACSL overexpression. Its associated lipotoxicity would 
be counteracted by SCD overexpression. Accordingly, x3 
cells have 20% less fat content than No ORF cells (data not 
shown). Thus, either a more efficient energetic use of lipids 
or an abnormally increased metabolism allows malignant 
features of x3 cells. Their advantage does not rely on 
exogenous lipid supply as no variations were found when 
experiments were performed upon serum lipid depletion or 
serum content reduction (data not shown). Besides, there 
was no increase in lipid incorporation neither of oleic acid 
nor palmitic acid into lipid vesicles upon ACSL1, ACSL4 
or SCD overexpression (data not shown). In agreement 
with that, the described monoacylglycerol-lipase invasive 
signature also shows independence from extrinsic fatty 
acids supply [51].
The combined overexpression of ACSL1/ACSL4/
SCD shows a poorer outcome and higher risk of relapse 
when compared to the upregulation of each of the genes 
separately in stage II-CRC patients (Figure 4 and Table 1). 
This suggests an increased aggressiveness of tumors 
overexpressing ACSL/SCD network. This fatty acid 
metabolism switch that acts through an EMT program 
is thus an example of how different types of metabolic 
reprogramming can be used by tumors to increase their 
malignity depending on the needs and the environment 
(Figure 6). The combination of ACSL/SCD inhibitors 
synergistically reduces cancer cells viability without 
decreasing normal cells viability (Figure 5C, 5G and 5H). 
Furthermore, this is also effective in CRC cells resistant 
to conventional chemotherapy (Figure 5D). Therefore, 
this sort of “synthetic lethality” caused by the combined 
action of ACSL and SCD inhibitors represents a new way 
of addressing tumor metabolism and may designate the 
ACSL/SCD axis interference as a promising opportunity 
for cancer treatment.
MATERIALS AND METHODS
Cell culture
Colon cancer cell lines, normal colon cell lines, 
and HEK-293T cells, were obtained from American Type 
Culture Collection (ATCC, Manassas, VA, USA), cultured 
in DMEM supplemented with 10% FBS and maintained 
under standard conditions. SW620–5FU-R cells were 
generated by exposing parental cells to increasing 
concentrations of the drug for 15 months as previously 
described [44]. All cell lines were authenticated by 
microsatellite genotyping. The 3D on top assays were 
performed as previously described [56]. Cells were plated 
in Matrigel (BD Biosciences, Franklin Lakes, NJ. USA) 
at a density of 10000 cells per well in 24-well plates 
and cultured for up to a week. Images were captured 
using a Leica DM IL microscope (Leica Microsystems, 
Wetzlar, Germany), with a 10X Plan Fluotar objective and 
registered using Leica Application Suite (LAS, Leica).
Reagents
Commercial antibodies used are listed in 
Supplementary Table S2. Antibody against SCD-1 [57] 
was a kind gift from Dr. Jean-Baptiste Demoulin, Université 
Catholique de Louvain, Brussels, Belgium. Anti-human 
ACSL4 was generously provided by Dr. Stephen Prescott, 
University of Utah, Salt Lake, USA and Dr. Diana Stafforini, 
Huntsman Cancer Institute, University of Utah, USA, and 
used as indicated in [58]. Triacsin C was purchased from 
Santa Cruz (Santa Cruz, CA, USA); A939572 was from 
Biofine International (Biofine International Inc, Vancouver, 
Canada); Metformin, Phenformin, AICAR, NS-398 and Akt 
Inhibitor IV were from Sigma-Aldrich, (Sigma-Aldrich, St. 
Louis, MO, USA).
Lentivirus-mediated stable overexpression  
of ACSL1, ACSL4 and SCD
HEK 293T cells were transfected using Lipofectamine 
2000 (Life Technologies, Carlsbad CA, USA) with 
lentiviral vectors expressing ACSL1, ACSL4, SCD or No 
ORF empty vector (DNA 2.0, Menlo Park CA, USA) along 
with a set of packaging plasmids (Addgene, Cambridge 
MA, USA). DLD-1 cells were infected with supernatant 
produced upon 48 hours transfection in HEK293T 
cells and 4 μg/μl polybrene (Millipore) as coadjutant. 
Selection was performed during 1 week by adding 
2 μg/ml puromycin, 3 μg/ml blasticidin, and 150 μg/
ml hygromycin, (Sigma) for SCD, ACSL4, and ACSL1 
constructs respectively.
Western blot
Cells were lysed in Laemmli buffer, proteins were 
separated by SDS–polyacrylamide gel electrophoresis 
and transferred onto a nitrocellulose membrane (Bio-Rad 
Laboratories, Hercules, CA, USA). The membranes 
were blocked using 5% nonfat dry milk in TBS 0.05% 
Tween-20. Primary antibodies were incubated overnight at 
4°C and upon 1 hour incubation with secondary antibodies 
signal detection was performed using the Clarity Western 
ECL Substrate (Bio-Rad). β-actin determination or 
Ponceau stain were used as loading controls.
Cell viability assay
Cell viability was determined by seeding 25000 
cells per well in 24-well plates and treated with the 
corresponding compounds for 48 hours. Upon treatment, 
cells were incubated 3 hours with 3-(4,5-dimethyl-thyazol-
2-yl)-2,5-diphenyl-tetrazolium (MTT, Sigma). The 
resultant formazan was dissolved in DMSO and its quantity 
determined by measuring absorbance at 560 nm. Data were 
expressed as the ratio of viable cells (%) which represents 
the percentage of viable cells upon treatment compared with 
the non-treated cells (100% ratio of viable cells).
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L-Lactate quantification
Cells were seeded at a density of 5000 cells per well 
in a 96-well plate. At 12 hours, medium was changed to 2% 
FBS and kept for 24 hours at 37°C before quantification. 
Using Cayman’s Glycolysis cell-based assay (Cayman, 
Ann Arbor, MI, USA, 600450) extracellular L-Lactate was 
measured by determining absorbance at 490 nm.
Quantitative real-time PCR
Total RNA was extracted using Tri Reagent 
(Sigma). 400 ng of RNA were reverse-transcribed using 
the High Capacity RNA-to-cDNA Master Mix system 
(Life Technologies). qPCR was performed in the 7900HT 
Real-Time PCR System (Life Technologies) using 
VeriQuest SYBR Green qPCR Master Mix (Affymetrix, 
Santa Clara, CA, USA) and gene specific primers listed 
in Supplementary Table S3. Values were corrected by 
GAPDH expression. The 2−∆∆Ct method was applied to 
calculate the relative gene expression.
Immunofluorescence
Cells were fixed with 4% paraformaldehyde for 
10 minutes at room temperature, then permeabilized 20 
minutes with 0.5% triton X-100, and stained with the 
primary antibody (1:100) followed with incubation with 
Alexa 488-conjugated anti-mouse secondary antibody 
(1:1000) and/or with DAPI (Prolong Gold antifade, Life 
Technologies) to visualize nuclei. Images were captured 
using a Leica DM IL microscope, with a 20X Plan Fluotar 
objective and registered using Leica Application Suite 
(LAS).
EdU incorporation assay
Cells were plated on coverslips and incubated 
24 hours before treatment with 10 μM EdU for 3 hours. 
In the case of the EdU assays in confluent conditions, 
EdU treatment was added once cells reached 
confluence. Cells were fixed with paraformaldehyde 
(4%) for 8 minutes and incorporation of EdU was 
Figure 6: ACSL/SCD-mediated tumor metabolic reprogramming. The combined action of ACSL1, ACSL4 and SCD confers an 
energetic advantage to tumor cells that stimulates several EMT-promoting and survival pathways. Lipid metabolism switches Warburg-like 
tumor metabolism into EMT-like tumor metabolism leading to a gain of mesenchymal and stem cell properties as well as migratory and 
invasive capabilities. This process can be reversed upon re-activation of AMPK signaling.
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assayed using Click-iT® EdU Alexa Fluor® 488 
Imaging Kit (Life Technologies). Coverslips were 
mounted on slides and nuclear DNA stained with 
DAPI. Images were captured using a Leica DM IL 
microscope, with a 40X Plan Fluotar objective and 
registered using LAS software.
Invasion assays
A density of 50000 cells was seeded into the inserts 
of a BD MatrigelTM invasion chamber (BD Biosciences) 
in serum-free DMEM. Medium containing 10% FBS 
was placed in the lower chamber as a chemoattractant. 
After 48 hours, inserts were fixed and stained with crystal 
violet, non-migrated cells removed using cotton swabs and 
images captured using an Olympus CKX41 microscope 
(Olympus, Tokyo, Japan), with a 20X LCAch objective 
and registered using analysis getIT software (Olympus)
Clonogenic assay
Single cell suspensions were seeded in 6-well plates 
at a density of 300 cells per well in 10% FBS DMEM. 
After 2 weeks, colonies were fixed and stained with crystal 
violet. Wells were photographed and colonies counted.
Wound healing assays
Cell migration was assayed using 24-well plates 
with IBIDI Culture-Inserts (IBIDI GmbH, München, 
Germany), where no cell damage occurs. 40000 cells were 
seeded into the two reservoirs of the same culture insert 
and incubated until confluence was reached. Inserts were 
removed and migration was monitored by taking pictures 
every 12 hours using a Leica DM IL microscope, with a 
10X Plan Fluotar objective.
Patients and samples
80 patients as training and 120 as validation set of 
stage II CRC patients undergoing surgery between 2000–
2004 and 2004–2008 respectively in La Paz University 
Hospital, were enrolled in the study. Formalin-Fixed, 
Paraffin-Embedded (FFPE) samples were obtained with 
the patient's authorization and with the approval of the 
human research Ethics review Committee of La Paz 
University Hospital (HULP-PI-1452). Inclusion criteria: 
Age ≥18, completely resected rectal cancer or colon 
adenocarcinoma located at ≥15 cm of the anal verge as 
determined by endoscopy or above the peritoneal reflection 
in the surgical resection, confirmed Stage II AJCC/
UICC primary CRC and follow-up of at least 36 months. 
Exclusion criteria: death within 30 days after surgery, 
other cancers in previous 5 years and inflammatory bowel 
disease or specific gene-related cancer.
Statistical analysis
Significance between groups was determined by 
t-test analyses. Data with P < 0.05 were considered 
statistically significant (*, P < 0.05; **, P < 0.01; ***, P 
< 0.001). Disease free survival (DFS) was estimated using 
Kaplan-Meier method. Log-rank test and Univariate Cox 
regression analysis was performed to test the association 
between DFS and gene expression. Hazard ratios (HR) 
and 95% CI were calculated from the Cox regression 
model, adjusted for potential confounding factors. All 
reported p values were two-sided. Statistical significance 
was defined as p < 0.05. The statistical analyses were 
performed using the R statistical software version 2.15 
(http://www.r-project.org).
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